EP Patent

EP1004309A1 — Israpafant-containing water-base preparations

Assigned to Senju Pharmaceutical Co Ltd · Expires 2000-05-31 · 26y expired

What this patent protects

Water-base preparations comprising an aqueous solution or suspension of israpafant represented by structural formula (I) and providing eye drops and nose drugs exhibiting excellent therapeutic effects against allergic conjunctivitis and rhinitis by local administration.

USPTO Abstract

Water-base preparations comprising an aqueous solution or suspension of israpafant represented by structural formula (I) and providing eye drops and nose drugs exhibiting excellent therapeutic effects against allergic conjunctivitis and rhinitis by local administration.

Drugs covered by this patent

Patent Metadata

Patent number
EP1004309A1
Jurisdiction
EP
Classification
—
Expires
2000-05-31
Drug substance claim
No
Drug product claim
No
Assignee
Senju Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.